dc.contributor.author | Akpınar, S. | |
dc.contributor.author | Tekgündüz, E. | |
dc.contributor.author | Erkurt, M.A. | |
dc.contributor.author | Esen, R. | |
dc.contributor.author | Yılmaz, M. | |
dc.contributor.author | Karakuş, V. | |
dc.contributor.author | Demirkan, F. | |
dc.date.accessioned | 2022-05-11T14:40:03Z | |
dc.date.available | 2022-05-11T14:40:03Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 14730502 | |
dc.identifier.uri | https://doi.org/10.1016/j.transci.2021.103312 | |
dc.identifier.uri | https://hdl.handle.net/20.500.11776/8846 | |
dc.description.abstract | Thrombotic microangiopathy(TMA) is a pathological diagnosis characterized by abnormalities of small vessels leading to microvascular thrombosis of arterioles and capillaries. The current prospective, non-interventional, multicenter (n:18) study aimed to define distribution of different TMA forms in adult Turkish patients who were referred for therapeutic plasma exchange (TPE) for a presumptive diagnosis of TMA. Patients with serum ADAMTS13 activity <5% were diagnosed as acquired thrombotic thrombocytopenic purpura (aTTP). Patients presenting with ADAMTS13 activity 6–10 % / normal renal function and patients with ADAMTS13 activity >10 %, normal renal function and no secondary TMA were treated as unclassified TMA. The study included a total of 97 patients (female: 60; male: 30) with a median age of 48 (18?74). Detailed evaluation at 1 month after hospital admission revealed aTTP, secondary TMA, infection/complement-associated hemolytic uremic syndrome and unclassified TMA in 32 (33 %), 33 (34 %), 26 (27 %) and 6 (6%) patients respectively. As subclassification of various TMAs will dictate specific therapy, proper diagnosis in a timely manner is of utmost clinical significance. © 2021 Elsevier Ltd | en_US |
dc.description.sponsorship | The present study was designed as an investigator initiated trial (IIT) and sponsored by Alexion Pharmaceuticals (Tracking number: 100064) | en_US |
dc.description.sponsorship | Alexion Pharmaceuticals: 100064 | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier Ltd | en_US |
dc.identifier.doi | 10.1016/j.transci.2021.103312 | |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Hematopoietic cell transplantation | en_US |
dc.subject | Hemolytic uremic syndrome | en_US |
dc.subject | Thrombotic microangiopathy | en_US |
dc.subject | Thrombotic thrombocytopenic purpura | en_US |
dc.title | Prospective registry of adult patients receiving therapeutic plasma exchange with a presumptive diagnosis of thrombotic microangiopathy (TMA): The Turkish hematology research and education group (ThREG)-TMA02 study | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Transfusion and Apheresis Science | en_US |
dc.department | Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.institutionauthor | Akpınar, Seval | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.authorscopusid | 14219156500 | |
dc.authorscopusid | 15756259700 | |
dc.authorscopusid | 8842895600 | |
dc.authorscopusid | 6507569757 | |
dc.authorscopusid | 7202595585 | |
dc.authorscopusid | 23061033300 | |
dc.authorscopusid | 6603070081 | |
dc.identifier.scopus | 2-s2.0-85119255512 | en_US |